The OSUCCC Genotyping and Sequencing Shared Resource (GSSR) - first established in 1997 as a restricted developing shared resource - has rapidly evolved into a state-of-the art DNA analysis facility providing an essential service available to and requested by the OSUCCC membership. The GSSR has demonstrated ability to handle large sequencing volumes, maintain high service quality, and accommodate a steadily increasing number of users. The GSSR has leveraged strong institutional support and user fees totaling $4.4 M to provide sequencing and genotyping performed by highly experienced personnel with outstanding quality control. The GSSR is located on the fourth floor of the Tzagournis Medical Research Facility with three other CCC SRs. The GSSR has one 48 capillary Applied Biosystems 3730 DNA Analyzer, one 96 capillary ABI PRISM? 3700 DNA Analyzer (to be replaced by an ABI 3730 in early 2004) and ancillary equipment for DNA sequencing and genotyping preparation. Now as a full SR, the GSSR has assumed a leading role in supporting molecular cancer research with state-of-the-art equipment, as well as developing novel methodologies that will become essential tools in the coming years for our membership. Specific goals for the sequencing and genotyping core are: (1) To provide affordable, high-throughput, high-quality genotyping and sequencing services in a timely manner. Genotyping will include screening methods for finding new polymorphisms (such as DHPLC) and scoring known polymorphisms. (2) To develop novel methodologies and applications relevant to cancer research, including genome-wide analys s of DNA methylation, gene silencing, and gene dosage, and large-scale genotyping panels (including haplotyping) targeted to cancer biology and therapeutics. (3) To train researchers and students in software utilization, data interpretation, and experimental strategies, conduct trouble shooting meetings with laboratory groups, and assist in the preparation of materials for publication. In the past year, usage of GSSR has increased 12% with now nearly 40 members from 3 CCC programs using the facility. The GSSR work has supported over 350 peer-reviewed publications (excluding reviews) since the last competitive renewal. Of these, 67 (19%) were in the 17 journals ranked highest by citation index (10-29.6). Building on this solid foundation, the task of the OSUCCC GSSR is to be an outstanding resource in the application of DNA analysis, in an era of rapid and profound technological advances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743476
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$193,036
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Li, Jingyi; Xu, Jie; Abruzzo, Lynne V et al. (2018) Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget 9:10987-10994

Showing the most recent 10 out of 2602 publications